Poland
With a population of over 38.2 million, Poland is one of the most attractive countries of the region in the long term for foreign investors and trade partners. The conversion to a free market economy was begun early and is being pursued consistently. In recent year GDP growth rates have been 3,4 in real terms (average salaries in 2010 was 850 EUR).
The pharmaceutical market, measured by value of per capita consumption, continues grow, but still are relatively small at present. The main reason for this lies in the prices generic drugs as a trend expected by government. Polish companies show a market share of 25% by value, but 44% by volume. With the inevitable upward adjustment of local drug prices the environment for foreign suppliers should improve considerably, but being not far from other European markets/trends.
The reimbursement lists (100%, 50%, 30% state co-payment), are important in creating market. Structure of sales value, reimbursement and non-reimbursement products in 2010 was 56,5% to 43,5%. It is anticipated, however, that more fundamental pharmaceutical and economic interests will prevail in the longer term. In addition there will be further expansion of the OTC market. OTC market share is 22,3% of total market value and is stable/not growing.
Key facts and figures:
With a population of over 38.2 million, Poland is one of the most attractive countries of the region in the long term for foreign investors and trade partners. The conversion to a free market economy was begun early and is being pursued consistently. In recent year GDP growth rates have been 3,4 in real terms (average salaries in 2010 was 850 EUR).
The pharmaceutical market, measured by value of per capita consumption, continues grow, but still are relatively small at present. The main reason for this lies in the prices generic drugs as a trend expected by government. Polish companies show a market share of 25% by value, but 44% by volume. With the inevitable upward adjustment of local drug prices the environment for foreign suppliers should improve considerably, but being not far from other European markets/trends.
The reimbursement lists (100%, 50%, 30% state co-payment), are important in creating market. Structure of sales value, reimbursement and non-reimbursement products in 2010 was 56,5% to 43,5%. It is anticipated, however, that more fundamental pharmaceutical and economic interests will prevail in the longer term. In addition there will be further expansion of the OTC market. OTC market share is 22,3% of total market value and is stable/not growing.
Key facts and figures:
| Area: | 312'685 km2 | |||||||
| Capital: | Warsaw | |||||||
| Population: | 38.2 million | |||||||
| Currency: | Polish Zloty (PLN) | |||||||
| Volume of pharmaceutical market: | USD 6.678 billion (2010) | |||||||
| Of which imported drugs: | 70% | |||||||
| No. of hospitals: | 740 | |||||||
| No. of physicians: | 132'830 | |||||||
| No. of pharmacies: | 13'270 | |||||||
| Our subsidiary: | Ewopharma Sp. z o.o. | |||||||
| ul. Swietokrzyska 36 m. 16 | ||||||||
| PL-00 116 Warsaw | ||||||||
|
||||||||
| Employees: |
|
